Commercial assay for Tysabri (Natalizumab) developed to enable physicians to make data driven decisions on how to optimize the infusion schedule for their multiple sclerosis patients. SAN DIEGO, Calif. (PRWEB) August 30, 2018 — Abreos Biosciences, a leader in the precision dosing of biological therapeutics, is pleased to announce a collaboration with ResearchDx, a recognized […]
Association for Molecular Pathology (AMP)
Irvine, CA — Oct 1, 2018 — PacificDx will be at the Association of Molecular Pathology (AMP) in San Antonio, Texas, November 1–3, 2018. Please visit us at the ResearchDx booth #602, or call us at 866.225.9195 or 949.812.6901 to set up a consultation at the show.
ResearchDx and Menarini Silicon Biosystems Launch DEPArray HER2 for Breast and GEA Cancers
Irvine, CA—October 2, 2017—ResearchDx, the leading biopharma companion diagnostics provider and Menarini Silicon Biosystems, worldwide manufacturer of image-based cell sorting products and services, jointly announce the launch of DEPArray HER2. The fluorescence in situ hybridization (FISH)-based assay has been validated as a clinical research laboratory developed test (LDT) and is performed by PacificDx, a CAP/CLIA certified and […]
Finding Needles in the Tumor Haystack: Single Cell HER2 Testing with DEPArray™ NxT Technology
Inside the heterogeneous tumor tissue samples sent to clinical pathology laboratories for HER2 gene testing are cancer genomes with their own inherent complexity. The biopsy (or surgical excision) tissue represents a mixture of genomes from the tumor and normal stroma. Further compounding the heterogeneity problem, tumor genomes harboring HER2 gene amplifications may have amplified HER2 […]
Surveying Genomic Landscapes in the Clinical Laboratory: DNA Views of Tumor Terrain
A web search for the term ‘genomic landscapes’ brings up a surprising number of publications from esteemed journals such as Cell, Science, and Nature Genetics. At first glance it would seem that the words ‘genomic’ and ‘landscape’ do not belong together. However, review of the many ‘genomic landscape’ publications from the past decade reveals a […]
ResearchDx And BioSmartSA Announce New Consulting Practice in Saudi Arabia
Irvine, California and Riyadh, Saudi Arabia, May 17, 2016 — ResearchDx, the premier Contract Diagnostics Organization (CDO) for the biopharmaceutical industry, and BioSmartSA, a healthcare consultancy based in Saudi Arabia, have formed a partnership to bring their expertise in navigating the design and management of diagnostic services to healthcare providers in the Kingdom of Saudi Arabia […]
ResearchDx, Inc. and PacificDx Expand Clinical CLIA Laboratory and Office Space to Accommodate New Research Partners and Assays
Leading contract diagnostics organization has completed construction of a 12,000 square foot addition to their office in Irvine, CA creating a 30,000 square foot headquarters in Irvine, CA. ResearchDx, Inc. announced the completion of a major construction addition to their Orange County headquarters in Irvine California. The company’s building at 5 Mason in Irvine, CA […]
Guidelines to the Galaxy of HER2 Testing in GEA Cancers
Say the words “HER2 gene amplification” and what immediately comes to mind is breast cancer. But did you know other cancers, including those of the stomach and esophagus (collectively called gastroesophagel adenocarinoma or GEA) can have too many (> 6) copies of the HER2 gene? That’s right, an estimated 20% of GEA cancers harbor an […]
ResearchDx/PacificDx to Present High-Resolution HER2 Testing Data at the San Antonio Breast Cancer Symposium
Leading contract diagnostics organization demonstrates the value of DNA-based testing for identifying the HER2-Low genomic subtype in high-risk HER2 equivocal breast cancer Irvine, CA—December 1, 2016—ResearchDx/PacificDx announced today that it will share findings demonstrating the value of DNA microarray comparative genomic hybridization (array CGH) for HER2 genomic subtyping in breast cancer patients at this year’s San […]
A Single Blood Test for All Cancers?
What if a simple blood test could detect any cancer early, when it was still easy to treat? It sounds like science fiction. But Illumina ILMN +5.20%, the $24 billion (market cap) biotechnology company that has pioneered cheap, efficient sequencing of DNA, says it could be a reality in a few years. It is launching […]